CDNA
Caredx Inc

3,227
Mkt Cap
$999.85M
Volume
27.00
52W High
$25.15
52W Low
$10.96
PE Ratio
16.30
CDNA Fundamentals
Price
$19.44
Prev Close
$19.63
Open
$19.53
50D MA
$19.69
Beta
1.47
Avg. Volume
778,677.25
EPS (Annual)
$0.9281
P/B
3.21
Rev/Employee
$513,515.39
$979.96
Loading...
Loading...
News
all
press releases
CareDx to Participate in the Raymond James 47th Annual Institutional Investors Conference
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue...
Business Wire·1h ago
News Placeholder
More News
News Placeholder
Zweig DiMenna Associates LLC Buys 348,400 Shares of CareDx, Inc. $CDNA
Zweig DiMenna Associates LLC increased its position in CareDx, Inc. (NASDAQ:CDNA - Free Report) by 153.8% during the third quarter, according to the company in its most recent 13F filing with the...
MarketBeat·1d ago
News Placeholder
CareDx (CDNA) Projected to Post Earnings on Tuesday
CareDx (NASDAQ:CDNA) will be releasing its Q4 2025 earnings before the market opens on Tuesday, February 24. (View Earnings Report at...
MarketBeat·1d ago
News Placeholder
CareDx Reports Positive Data for AlloHeme in AML and MDS Post HCT
CDNA shares climb after AlloHeme data show early AML/MDS relapse detection, backing its Transplant+ expansion into cell therapy markets.
Zacks·2d ago
News Placeholder
CareDx Expands Transplant Plus Into Cell Therapy, Showcases AlloHeme AML/MDS Relapse Data
CareDx (NASDAQ:CDNA) used an investor webcast to outline its Transplant Plus expansion into cell therapy and to highlight new data supporting AlloHeme, a blood-based test designed to predict relapse...
MarketBeat·5d ago
News Placeholder
CareDx Announces Clinical Validation Results for AlloHeme, the First AIPowered NGS Surveillance Solution for AML and MDS PostCell Therapy
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue...
Business Wire·6d ago
News Placeholder
CareDx, Inc. $CDNA Stock Holdings Lessened by New York State Common Retirement Fund
New York State Common Retirement Fund lessened its stake in shares of CareDx, Inc. (NASDAQ:CDNA - Free Report) by 79.7% in the third quarter, according to its most recent filing with the SEC. The...
MarketBeat·6d ago
News Placeholder
CareDx, Inc. (NASDAQ:CDNA) Receives Consensus Rating of "Hold" from Brokerages
Shares of CareDx, Inc. (NASDAQ:CDNA - Get Free Report) have earned a consensus recommendation of "Hold" from the nine brokerages that are currently covering the stock, Marketbeat reports. Six...
MarketBeat·8d ago
News Placeholder
CareDx (NASDAQ:CDNA) Cut to "Hold" at Wall Street Zen
Wall Street Zen downgraded CareDx from a "buy" rating to a "hold" rating in a research report on Saturday...
MarketBeat·11d ago
News Placeholder
CareDx to Present AlloHeme Pivotal Clinical Validation Data in Hematologic Cancer Relapse Detection at 2026 Tandem Meetings
CareDx, Inc. (Nasdaq: CDNA) The Transplant Company, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, highvalue...
Business Wire·15d ago
<
1
2
...
>

Latest CDNA News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.